Fatigue News and Research

RSS

Ablation can lead to better outcomes for patients with advanced atrial fibrillation

A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced forms of atrial fibrillation, according to a major international clinical trial led by researchers at the University of British Columbia.

27 Apr 2026

New AI tools enhance diagnosis and management of kidney disease

Kidney diseases develop slowly and may not produce any obvious symptoms for a long time. The body can compensate for them so effectively that the patient remains unaware of the problem for years.

25 Apr 2026

Losing weight improves heart muscle contraction in people with obesity and heart failure

In a new research report, a team of scientists led by Johns Hopkins Medicine say people with severe obesity and a common type of heart failure experience weakened heart muscles, and that losing weight may reverse some of these effects.

25 Apr 2026

Email alerts boost valve replacement rates in older patients with aortic stenosis

New data finds older patients with severe aortic stenosis (AS) were more likely to receive aortic valve replacement (AVR) and survive when clinicians received automated email notifications with abnormal heart ultrasound results detecting AS.

25 Apr 2026

Novel algorithm improves detection of moderate-to-severe aortic stenosis

A novel detection algorithm spotted moderate-to-severe aortic stenosis (AS) with a sensitivity of 90.5% of all patients and 100% of African American patients.

24 Apr 2026

Drinking coffee alters your microbiome, mood, and memory

Coffee consumption influences the microbiota-gut-brain axis, affecting cognitive performance and emotional regulation through complex biological pathways.

24 Apr 2026

Can exercise or ibuprofen fight chemo brain?

This study suggests exercise can mitigate cancer-related cognitive impairment, but combining it with ibuprofen offers no additional cognitive benefits.

23 Apr 2026

Triple combination pill reduces recurrent stroke risk

Treatment with GMRx2, a single pill combination of three low-dose blood pressure medicines, significantly reduced the risk of another stroke in patients with intracerebral hemorrhage and high blood pressure.

22 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

Patient outcomes vary by drug class despite achieving clinical remission

A study published in Rheumatology & Autoimmunity challenges the assumption that achieving clinical remission in rheumatoid arthritis is sufficient, showing that patient-reported outcomes vary significantly by drug class even when disease activity is comparable.

22 Apr 2026

Survey of families suggests high risks for electroconvulsive therapy

Electroconvulsive therapy (ECT), which involves passing electricity through the brain under general anesthesia to cause a seizure, usually between six and twelve times, is used to varying degrees around the world for patients with depression and other mental conditions.

22 Apr 2026

Injectable immunotherapy shrinks precancerous oral lesions in clinical trial

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

Millions of Americans with hepatitis C still remain untreated, analysis reveals

Millions of Americans are still battling potentially deadly hepatitis C even though they could be cured with antiviral drugs they are not receiving, a new analysis reveals.

21 Apr 2026

Ibuprofen shown to improve cognitive function in patients undergoing chemotherapy

Researchers have already shown that mild to moderate exercise can reduce "chemo brain," and a new study suggests that a low dose of an over-the-counter anti-inflammatory, ibuprofen, can also achieve positive results for cancer patients.

21 Apr 2026

Muscle energy recovery may explain fatigue in cancer survivors

Even apparently healthy cancer survivors often complain of extreme fatigue. They have finished treatment, the scans are clear, but they feel hollowed out, unable to walk to the mailbox or stay awake through dinner.

21 Apr 2026

Stem cell model identifies promising therapy for inflammatory bowel disease

A new study published today in Stem Cell Reports demonstrates how a human stem cell-derived model of the intestine can be used to identify potential therapies for inflammatory bowel disease (IBD), highlighting glycyrrhizin as a promising candidate for reducing intestinal inflammation and cell death.

17 Apr 2026

Experimental drug shows survival benefit in pancreatic cancer trial

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis.

14 Apr 2026

Study finds long COVID leaves a distinct immune signature in the blood

Researchers identified a small panel of inflammatory and neurology-related blood proteins that may help distinguish long COVID from recovery or no prior infection, while also showing that booster vaccination did not appear to worsen these protein responses in this cohort. The study also found that immune responses after reinfection differed from those seen after the first SARS-CoV-2 infection, suggesting altered long-term immune behavior in some previously infected individuals.

14 Apr 2026

Beetroot supplement raises nitric oxide markers in triathletes after one week

A randomized cross-over pilot study in 10 amateur male triathletes found that a beetroot-based multi-ingredient nitrate supplement increased nitric oxide-related and redox biomarkers over 7 days without evidence of lipid oxidative damage. The supplement was generally well tolerated, but the study did not measure whether these biochemical changes improved performance or recovery.

13 Apr 2026

Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40 %, in adults in the UK.

From Bayer PLC 13 Apr 2026